BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...Alnylam gained the remaining 50% of the rights to the Kreutzer-Limmer patents when it acquired Ribopharma AG...
BioCentury | May 31, 2010
Finance

Performance Counts

...return. Bunting also cited the return on Abingworth's 2003 seed investment of $2.2 million in Ribopharma AG...
...deal for an undisclosed amount. "We knew that Alnylam would be forced to merge with Ribopharma...
...it had the top IP- the most important patents in the space were held by Ribopharma...
BioCentury | Sep 14, 2009
Company News

Alnylam chemistry news

...the 3' end of the molecule. Alnylam gained the technology through its 2003 acquisition of Ribopharma AG...
BioCentury | Mar 15, 2004
Tools & Techniques

atugen's blunt approach to RNAi

...total of $43 million since July 2002, which includes funds raised by German merger partner Ribopharma AG...
BioCentury | Feb 2, 2004
Company News

Alnylam, RNAx deal

...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the use...
...RNAx's research services business. RNAx will pay initial and annual license fees plus royalties to Ribopharma...
BioCentury | Jul 14, 2003
Company News

Alnylam, Ribopharma deal

...to fund operations for about three to five years. Alnylam Pharmaceuticals Inc. , Cambridge, Mass. Ribopharma AG...
BioCentury | Jul 14, 2003
Company News

Alnylam Holding Co. management update

...Co. ; and Roland Kreutzer to COO of the Ribopharma operating unit from CEO at Ribopharma AG WIR...
BioCentury | Jul 7, 2003
Company News

Alnylam, Ribopharma merge

...RNAi companies Alnylam (Cambridge, Mass.) and Ribopharma (Kulmbach, Germany) merged to focus on developing therapeutics in...
...CEO of the combined company, and Ribopharma CEO Roland Kreutzer will be COO of the Ribopharma...
BioCentury | Feb 17, 2003
Company News

Ribopharma scientific advisory board update

Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Rossi, chair of the division of molecular biology at the Beckman Research Institute of the City of Hope Hospital; Ronald Plasterk, institute director of the Hubrecht Laboratory...
BioCentury | Feb 3, 2003
Company News

Ribopharma board of directors update

Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Berriman, director of Abingworth WIR Staff...
Items per page:
1 - 10 of 12
BioCentury | Apr 15, 2013
Strategy

IP armamentarium

...Alnylam gained the remaining 50% of the rights to the Kreutzer-Limmer patents when it acquired Ribopharma AG...
BioCentury | May 31, 2010
Finance

Performance Counts

...return. Bunting also cited the return on Abingworth's 2003 seed investment of $2.2 million in Ribopharma AG...
...deal for an undisclosed amount. "We knew that Alnylam would be forced to merge with Ribopharma...
...it had the top IP- the most important patents in the space were held by Ribopharma...
BioCentury | Sep 14, 2009
Company News

Alnylam chemistry news

...the 3' end of the molecule. Alnylam gained the technology through its 2003 acquisition of Ribopharma AG...
BioCentury | Mar 15, 2004
Tools & Techniques

atugen's blunt approach to RNAi

...total of $43 million since July 2002, which includes funds raised by German merger partner Ribopharma AG...
BioCentury | Feb 2, 2004
Company News

Alnylam, RNAx deal

...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the use...
...RNAx's research services business. RNAx will pay initial and annual license fees plus royalties to Ribopharma...
BioCentury | Jul 14, 2003
Company News

Alnylam, Ribopharma deal

...to fund operations for about three to five years. Alnylam Pharmaceuticals Inc. , Cambridge, Mass. Ribopharma AG...
BioCentury | Jul 14, 2003
Company News

Alnylam Holding Co. management update

...Co. ; and Roland Kreutzer to COO of the Ribopharma operating unit from CEO at Ribopharma AG WIR...
BioCentury | Jul 7, 2003
Company News

Alnylam, Ribopharma merge

...RNAi companies Alnylam (Cambridge, Mass.) and Ribopharma (Kulmbach, Germany) merged to focus on developing therapeutics in...
...CEO of the combined company, and Ribopharma CEO Roland Kreutzer will be COO of the Ribopharma...
BioCentury | Feb 17, 2003
Company News

Ribopharma scientific advisory board update

Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Rossi, chair of the division of molecular biology at the Beckman Research Institute of the City of Hope Hospital; Ronald Plasterk, institute director of the Hubrecht Laboratory...
BioCentury | Feb 3, 2003
Company News

Ribopharma board of directors update

Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Berriman, director of Abingworth WIR Staff...
Items per page:
1 - 10 of 12